Navigation Links
ProEthic Pharmaceuticals Presents Positive Data for PRO-513 at,American Headache Society Meeting

MONTGOMERY, Ala.--(BUSINESS WIRE)--Jun 8, 2007 - ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops, licenses, and markets niche prescription products, today presented detailed Phase III study data for PRO-513, the Company's product candidate for the treatment of migraine headaches. The results were presented in two poster presentations at the American Headache Society's 49th Annual Scientific Meeting in Chicago by Richard B. Lipton, MD, Professor and Vice Chair of Neurology at the Albert Einstein College of Medicine and Director of the Montefiore Headache Center. The findings showed that PRO-513 relieved the pain of migraine for patients within 30 minutes, reduced the associated symptoms of the migraine attack and that its benefits persisted up to 24 hours.

The first poster presentation provided efficacy and tolerability results from a Phase III clinical study for PRO-513, a randomized, double-blind, placebo-controlled trial that enrolled 690 adult patients.

The two-hour pain free response among patients, the primary efficacy endpoint of the trial, was 25 percent in the PRO-513 arm of the trial versus 10 percent for the placebo arm (P less than 0.001). In addition, the two-hour pain headache response for the PRO-513 arm of the trial was 65 percent, compared with 41 percent for the placebo group. Statistically significant differences in pain intensity difference (PID) scores emerged at 30 minutes (P=0.013) and the PID remained significant at P less than 0.001 at each of the subsequent 10 time points measured.

The findings also demonstrated that the proportion of patients who were free of symptoms accompanying migraine was statistically significant for PRO-513 compared to placebo at two hours for nausea (P=0.002), photophobia, or sensitivity to light (P less than 0.001) and phonophobia, or sensitivity to sound (P less than 0.001).

The
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ("Sony") ... 8-well strip holder and 130um sorting chip.  Sony will also ... on its new SH800 Cell Sorter, the EC800 flow cytometer, ... tutorials at CYTO 2013, which will be held at the ... San Diego, California , from May 20 - ...
(Date:5/17/2013)... announced that it will report its 2013 first quarter earnings on Wednesday, ... Ed Borkowski , CFO, will host an analyst and investor ... participate in the conference call within the U.S. and Canada ... call outside the U.S. and Canada , dial (760) ... should dial in 10 minutes prior to the start of the call. ...
(Date:5/17/2013)... , May 17, 2013  PENTAX Medical, ... Hitachi-Aloka Medical, a global leader in ultrasound imaging, ... global companies to enable further innovation in the ... the Hitachi-Aloka ultrasound systems and PENTAX Medical endoscopic ... trusted families of EUS systems. This agreement will ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3
... Anpath Group, Inc.,(OTC Bulletin Board: ANPG), reported ... announced the selection of its,disinfectant, EnviroTru(TM) for ... (Metro). EnviroTru(TM) is a multi-purpose disinfectant ... also meets EPA requirements for,Toxicity Category IV ...
... of statins treated for 3 months with 200 mg/week mipomersen experienced ... continues to support mipomersen,s ... safety profile,- Isis hosting Analyst & Investor Day today - webcast live at 9:00 ... at http://www.isispharm.com , ...
Cached Medicine Technology:Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 2Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 4Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 5Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 6Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 7
(Date:5/18/2013)... Orlando, FL (May 18, 2013) The use ... for a colonoscopy, according to new research presented ... process, which begins days in advance of the ... preparation medication to be taken at strict intervals. ... for doctors to see cancer and precancerous polyps ...
(Date:5/18/2013)... 18, 2013) A ground-breaking advance in colonoscopy ... to research presented today at Digestive Disease Week ... withdrawal time for colonoscopies and exploring safer methods ... doctors use a device called a colonoscope to ... cancer allows a doctor to look for precancerous ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... Wright, KY (PRWEB) May 18, 2013 ... with hearing loss should consider the legal protections they ... claim, when problems arise with their child’s treatment or ... today. , Since 1927, the American Speech-Language-Hearing Association has ... communication disorders and to promote treatment, such as cochlear ...
(Date:5/18/2013)... Florida (PRWEB) May 18, 2013 Adolescents, ... also known as “Spice” or “K2” are landing in ... helping to curb this drug epidemic with a ... synthetic marijuana. , According to research from the National ... second-most popular illegal drug among American teenagers. In 2012, ...
Breaking Medicine News(10 mins):Health News:New smartphone application improves colonoscopy preparation 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2
... may take her many steps forward in her career but is ... well known that stress influences eating pattern. A study conducted by ... to adopt certain unhealthy behavior upon working long hours, which can ... or consume too many snacks and may even go overboard on ...
... vocal cord dysfunction (VCD) – an involuntary functional disorder ... in a long-term study published in the current issue ... journal of the American College of Allergy, Asthma and ... and Pulmonary Division at the University of Iowa College ...
... be a wake up call to get the duvets washed and ... their duvets even in six months, and these could// be the ... ,A survey conducted in many households revealed that two ... months. The dust mites and filth are potential health hazards ...
... United Kingdom have lone inhabitants, which means there is a ... surely// an unhealthy trend, say Danish researchers, whose study has ... disease. ,The living alone and ill health ... the 30-69 age bracket. Their lives were studied in detail ...
... Queensland have been reviewed following allegations of inaccuracy by the ... Stephen Robertson there was an unusually low pickup of cancer ... ,9,300 cases were reviewed. Among these 83 women had ... non-malignant cancers. ,Two Gold Coast women are suing ...
... to a large-scale study published in the July issue of ... discontinued the use of Uprima// , a drug known to ... the success rates of this drug. ,And 70 ... an official National Health Service (NHS) drug feedback form felt ...
Cached Medicine News:Health News:Two Distinct Types of Vocal Cord Dysfunction Identified 2Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 2Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 3
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
AchilloTrain is a comfortable knitted support with a silicone insert alongside the Achilles tendon and under the heel. An additional heel cushion is provided for the unaffected foot. It is worn to tr...
DarcoGel™ Upper chamber is foam filled, conforms to calf; gel-filled lower chamber molds to the malleoli for a custom fit. Freeze the removable liner for cold therapy. One size. Fits left or ri...
... maintaining the ankle in functional alignment. Entire ... cushioning AliPlast™ foam liner. The cushioning air ... heel in a protective hammock, reducing ulceration ... bed from side-lying to supine. Only the ...
Medicine Products: